Bionomics Limited (BNOX)
After hours:
| Previous Close | 0.9663 |
| Open | 0.9900 |
| Bid | 0.7000 x 200 |
| Ask | 1.2300 x 200 |
| Day's Range | 0.9336 - 1.0000 |
| 52 Week Range | 0.8700 - 6.4100 |
| Volume | |
| Avg. Volume | 131,603 |
| Market Cap | 10.693M |
| Beta (5Y Monthly) | -0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3400 |
| Earnings Date | Apr 29, 2024 - May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
GlobeNewswireBionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments. Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210’s registrational program in PTSD by e
Simply Wall St.Bionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)
Bionomics ( NASDAQ:BNOX ) First Half 2024 Results Key Financial Results Net loss: AU$15.4m (loss narrowed by 5.2% from...
- GlobeNewswire
Bionomics to Present at the 2024 BIO CEO & Investor Conference
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY. Spyros Papapet
